AstraZeneca’s latest antibody to prevent Covid-19 hit on both of its primary endpoints in a large Phase 3 trial, the UK company said Thursday.
The preventive treatment known as sipavibart, which will likely serve as a successor to AstraZeneca’s Covid blockbuster drug Evusheld, reduced the incidence of symptomatic Covid-19 when compared to Evusheld or placebo among immunocompromised patients in the trial.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.